Predictive parameters in biologic assessment of low-stage retroperitoneal lymph-node dissection

P. Albers, W. deRiese, E. B. Walker, Thomas Ulbright, W. N. Crabtree, T. Reister, Richard Foster, J. P. Donohue

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In all, 30% of patients felt to have clinical stage A nonseminomatous testis cancer in fact have pathologic stage B disease. Although patients with clinical stage A nonseminoma currently enjoy a very high change for cure, a better assignment of therapy at diagnosis could lead to an overall decrease in the morbidity of treatment. This study analyzed orchiectomy specimens from 102 patients with clinical stage A nonseminomatous testis cancer, all of whom underwent pathologic staging via retroperitoneal lymph-node dissection (RPLND). Various parameters of the orchiectomy specimen were analyzed to determine wheter or not clinical staging could be improved on the basis of these factors. Statistical analysis resulted in the following model. If the orchiectomy specimen consisted of 100% embryonal carcinoma the patient was classified as being at high risk for retroperitoneal metastasis. In the absence of this finding the aneuploid cell line as determined by flow cytometry was considered. If the percentage of aneuploid cells in the S phase was less than 29% the patient was felt to be at low risk for retroperitoneal metastasis. If this percentage was greater than 29% the patient was classified as being at high risk. Using this paradigm, 77% of pathologic stage A patients and 91% of pathologic stage B patients were correctly classified. The test efficiency was 82%. This pilot study resulted in an interesting model that should be tested prospectively in consecutive patients to determine whether it is clinically useful.

Original languageEnglish
Pages (from-to)120-124
Number of pages5
JournalWorld Journal of Urology
Volume12
Issue number3
DOIs
StatePublished - Jun 1994

Fingerprint

Lymph Node Excision
Orchiectomy
Testicular Neoplasms
Aneuploidy
Embryonal Carcinoma
Neoplasm Metastasis
S Phase
Flow Cytometry
Morbidity
Cell Line
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

Albers, P., deRiese, W., Walker, E. B., Ulbright, T., Crabtree, W. N., Reister, T., ... Donohue, J. P. (1994). Predictive parameters in biologic assessment of low-stage retroperitoneal lymph-node dissection. World Journal of Urology, 12(3), 120-124. https://doi.org/10.1007/BF00192266

Predictive parameters in biologic assessment of low-stage retroperitoneal lymph-node dissection. / Albers, P.; deRiese, W.; Walker, E. B.; Ulbright, Thomas; Crabtree, W. N.; Reister, T.; Foster, Richard; Donohue, J. P.

In: World Journal of Urology, Vol. 12, No. 3, 06.1994, p. 120-124.

Research output: Contribution to journalArticle

Albers, P. ; deRiese, W. ; Walker, E. B. ; Ulbright, Thomas ; Crabtree, W. N. ; Reister, T. ; Foster, Richard ; Donohue, J. P. / Predictive parameters in biologic assessment of low-stage retroperitoneal lymph-node dissection. In: World Journal of Urology. 1994 ; Vol. 12, No. 3. pp. 120-124.
@article{0bff287b268d446fa672170dceedb5a5,
title = "Predictive parameters in biologic assessment of low-stage retroperitoneal lymph-node dissection",
abstract = "In all, 30{\%} of patients felt to have clinical stage A nonseminomatous testis cancer in fact have pathologic stage B disease. Although patients with clinical stage A nonseminoma currently enjoy a very high change for cure, a better assignment of therapy at diagnosis could lead to an overall decrease in the morbidity of treatment. This study analyzed orchiectomy specimens from 102 patients with clinical stage A nonseminomatous testis cancer, all of whom underwent pathologic staging via retroperitoneal lymph-node dissection (RPLND). Various parameters of the orchiectomy specimen were analyzed to determine wheter or not clinical staging could be improved on the basis of these factors. Statistical analysis resulted in the following model. If the orchiectomy specimen consisted of 100{\%} embryonal carcinoma the patient was classified as being at high risk for retroperitoneal metastasis. In the absence of this finding the aneuploid cell line as determined by flow cytometry was considered. If the percentage of aneuploid cells in the S phase was less than 29{\%} the patient was felt to be at low risk for retroperitoneal metastasis. If this percentage was greater than 29{\%} the patient was classified as being at high risk. Using this paradigm, 77{\%} of pathologic stage A patients and 91{\%} of pathologic stage B patients were correctly classified. The test efficiency was 82{\%}. This pilot study resulted in an interesting model that should be tested prospectively in consecutive patients to determine whether it is clinically useful.",
author = "P. Albers and W. deRiese and Walker, {E. B.} and Thomas Ulbright and Crabtree, {W. N.} and T. Reister and Richard Foster and Donohue, {J. P.}",
year = "1994",
month = "6",
doi = "10.1007/BF00192266",
language = "English",
volume = "12",
pages = "120--124",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Predictive parameters in biologic assessment of low-stage retroperitoneal lymph-node dissection

AU - Albers, P.

AU - deRiese, W.

AU - Walker, E. B.

AU - Ulbright, Thomas

AU - Crabtree, W. N.

AU - Reister, T.

AU - Foster, Richard

AU - Donohue, J. P.

PY - 1994/6

Y1 - 1994/6

N2 - In all, 30% of patients felt to have clinical stage A nonseminomatous testis cancer in fact have pathologic stage B disease. Although patients with clinical stage A nonseminoma currently enjoy a very high change for cure, a better assignment of therapy at diagnosis could lead to an overall decrease in the morbidity of treatment. This study analyzed orchiectomy specimens from 102 patients with clinical stage A nonseminomatous testis cancer, all of whom underwent pathologic staging via retroperitoneal lymph-node dissection (RPLND). Various parameters of the orchiectomy specimen were analyzed to determine wheter or not clinical staging could be improved on the basis of these factors. Statistical analysis resulted in the following model. If the orchiectomy specimen consisted of 100% embryonal carcinoma the patient was classified as being at high risk for retroperitoneal metastasis. In the absence of this finding the aneuploid cell line as determined by flow cytometry was considered. If the percentage of aneuploid cells in the S phase was less than 29% the patient was felt to be at low risk for retroperitoneal metastasis. If this percentage was greater than 29% the patient was classified as being at high risk. Using this paradigm, 77% of pathologic stage A patients and 91% of pathologic stage B patients were correctly classified. The test efficiency was 82%. This pilot study resulted in an interesting model that should be tested prospectively in consecutive patients to determine whether it is clinically useful.

AB - In all, 30% of patients felt to have clinical stage A nonseminomatous testis cancer in fact have pathologic stage B disease. Although patients with clinical stage A nonseminoma currently enjoy a very high change for cure, a better assignment of therapy at diagnosis could lead to an overall decrease in the morbidity of treatment. This study analyzed orchiectomy specimens from 102 patients with clinical stage A nonseminomatous testis cancer, all of whom underwent pathologic staging via retroperitoneal lymph-node dissection (RPLND). Various parameters of the orchiectomy specimen were analyzed to determine wheter or not clinical staging could be improved on the basis of these factors. Statistical analysis resulted in the following model. If the orchiectomy specimen consisted of 100% embryonal carcinoma the patient was classified as being at high risk for retroperitoneal metastasis. In the absence of this finding the aneuploid cell line as determined by flow cytometry was considered. If the percentage of aneuploid cells in the S phase was less than 29% the patient was felt to be at low risk for retroperitoneal metastasis. If this percentage was greater than 29% the patient was classified as being at high risk. Using this paradigm, 77% of pathologic stage A patients and 91% of pathologic stage B patients were correctly classified. The test efficiency was 82%. This pilot study resulted in an interesting model that should be tested prospectively in consecutive patients to determine whether it is clinically useful.

UR - http://www.scopus.com/inward/record.url?scp=0028247488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028247488&partnerID=8YFLogxK

U2 - 10.1007/BF00192266

DO - 10.1007/BF00192266

M3 - Article

VL - 12

SP - 120

EP - 124

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 3

ER -